Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ADR-001 in compensated liver cirrhosis
jRCT2033210425Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Feb 2022
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ADR-001 in Cirrhosis, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Change in albumin-bilirubin score. Started Feb 2022; status: completed.
02
Drugs
ADR-001
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on jRCT2033210425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033210425.